"The primary end point was met, showing a statistically significant rPFS benefit with the combination of capivasertib and abiraterone," said Karim Fizazi, MD, PhD. Adding the oral AKT inhibitor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback